This study - designed, executed and analyzed by research professionals from the drug development and commercialization industry - sheds light on prescribers' views of biosimilars. It is based on interviews with 264 physicians in the United States and Western Europe.
PhRMA’s 2012 Medicines in Development for Cancer report includes information on new oncology drugs in the pipeline and their current development status. The report is broken down by type of cancer and is followed by additional fact sheets and other helpful resources. Our goal is that the report not just serve as an informational resource, but as a source of hope as our sector continues to invest in research for a better future.
Survey Results Identify Key Trends Related to Oral Meds, RA Management, Cost of Therapy, and More
The completely updated, revised, and expanded 2012
For anyone who wants to understand and benefit from the forces reshaping the highly competitive U.S. pharmacy industry, the 2012
Downloadable PDF By Adam J. Fein, Ph.D.
This report provides pharmaceutical and biotech organizations an opportunity to benchmark their own Health Economics and Outcomes Research (HEOR) approaches against that of Top 50 Pharma companies. Download Report Preview here. (Source: ISR reports, 2013).
Datamonitor has identified a total of 397 biosimilars/copy-biologics across 125 companies as being in development/marked. Products and pipeline candidates were identified using publically available information (where available). For each candidate, the stage of development was determined using company reported information as well as secondary sources such as clinical trial databases.
The research report aims to analyze and assess the global generics pharmaceutical market, map the key trends and dynamics shaping the industry sector and provide strategic recommendations for the success of the market participants. With several key blockbuster drugs losing patent protection and new healthcare reforms being introduced by the Governments, the generics pharmaceutical market is on a growing curve. This study provides an in-depth knowledge of the key national markets and therapeutic areas presenting significant growth opportunities for generics, consolidation trends in the industry and impact of regulation on each of the markets.
This Healthcare Intelligence Network (HIN) report, Guide to Value-Based Reimbursement: Profiting from Payment Bundling, PHO Shared Savings, and Pay for Performance, explores emerging models of episode-based payments, physician-hospital organizations and physician bonus structures.
Purchase your copy here.
Pricing pressure and regulatory restrictions across various healthcare industries have called for more detailed
evidence of outcomes of healthcare products. In order to gain market access, medical technology manufacturers
must be able to demonstrate the clinical and economic evidence to providers, healthcare decision-makers and
payers to be able to remain competitive.